) show a protective action against "ischemiareperfusion" stress of neonatal rat ventricular cardiomyocytes (NRCs) in culture.
Introduction.
In recent years carbon monoxide (CO) has been acknowledged as a fundamental (small-molecule) gaseous messenger in humans. 2 The endogenous production of CO is associated with the heme metabolic pathway and the action of a family of enzymes known as heme oxygenases (HO's). 2 HO's catalyze the oxidation of heme to biliverdin resulting in the production of free iron and CO (scheme 1).
The distribution of HO's is strictly tissue specific and HO-derived CO carry on a number of local physiological functions. Carbon monoxide acts as a signaling molecule in cytoprotective signaling cascade activated by various stress stimuli. 3, 4 Similar to nitric monoxide, it plays a fundamental role in the circulatory system by improving vasorelaxation and cardiac blood supply. [5] [6] [7] [8] [9] CO also appears to influence neurotransmission in the hypothalamic-pituary-adrenal axis like NO [10] [11] [12] and there is evidence that CO might influence our circadian rhythm 13 (the 24-hour cycle in the biochemical, physiological or behavioural processes) by interacting with NPAS2 (the human "clock" protein). 14 Furthermore, carbon monoxide was reported to attenuate arteriosclerotic lesions associated with chronic graft rejection.
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Scheme 1. Heme-catalyzed endogenous production of CO.
As the importance of CO is increasingly recognized, there is a growing interest in the pharmacological and medicinal applications of carbon monoxide. [16] [17] [18] [19] [20] [21] [22] Direct inhalation of CO has been viewed as a novel therapeutic approach but reports on tolerance to CO exposure are contradictory. 4, 23, 24 There is a very delicate balance between CO induced tissue hypoxia and therapeutic effects.
Furthermore, the direct use of the gaseous molecule poses problems associated with its safe handling and delivery to specific target sites in a controlled and measurable fashion. An alternative approach to the administration of carbon monoxide is the use of CO-releasing molecules (CO-RMs). An obvious choice for CO-RMs are transition metal carbonyl complexes with one or more CO ligands.
Several complexes have been evaluated to date, 19, [25] [26] [27] [28] [29] [30] [31] but the pioneering work of Motterlini and Mann has resulted in the discovery of the fac-[RuCl(glycinato)(CO) 3 ] complex (CORM-3) as the most promising compound for the CO release in vivo. 5, [32] [33] [34] The chemistry and therapeutic effects of CORM-3 are well documented. The Ru complex releases 1 mol of CO within 10 min after dissolving in water and it has been shown that CORM-3 significantly reduces blood pressure in vivo and relaxes precontracted aortic rings in vitro. 5, [32] [33] [34] The cardioprotective functions of CORM-3 have also been described. 5 We have recently reported that the one electron reduction of cis-[Re III (CO) 2 analysed with flame atomic absorption spectroscopy (F-AAS) using an AA240FS spectrometer (Varian AG, Zug, Switzerland). Crystallographic data were collected at 183(2) K with Mo K α radiation (λ = 0.7107 Å) that was monochromated with help of a graphite on an Oxford Diffraction Xcalibur system with a Ruby detector. Suitable crystals were covered with oil (Infineum V8512), mounted on top of a glass fiber and immediately transferred to the diffractometer. The program suite CrysAlis Pro was used for data collection, semi-empirical absorption correction and data reduction. 39 Structures were solved with direct methods using SIR97 40 and were refined by full-matrix least-squares methods on F 2 with SHELXL-97. 41 The structures were checked for higher symmetry with help of the program Platon. In Vitro Model of "Ischemia-Reperfusion" Stress of Cardiomyocyte.
Animal keeping, breeding and experimentation were reviewed, approved, and carried out in accordance with the Swiss animal protection laws and institutional guidelines. Neonatal rat ventricular cardiomyocytes (NRCs) were isolated from Wistar rat pups (postnatal day 3-4) as described elsewhere. 43 The cells were kept in culture for 4 days and then used for experiments. The culture medium was exchanges for a glucose-free medium titrated to pH 6.0 and the cells were placed into a hypoxic incubator and exposed to 1% O 2 , 5% CO 2 and 94% N 2 for 16 h to simulate ischemic conditions.
Thereafter, reperfusion was simulated by replacing the medium for one containing 5 mM glucose titrated to pH 7.4 and oxygen concentration in the incubator was increased to 20%. This protocol will be referred to as "ischemia-reperfusion" stress. The tested compounds were freshly dissolved in DMSO (30 mM stock solutions) before the experiment and added to obtain a final concentration of 30 µM immediately after the incubation medium was been changed (at the "onset of reperfusion"). A corresponding amount of DMSO was added to the control non-treated cells. 
Synthesis of [ReBr 2 (CO) 2 (BzIm) 2 ] (4)
. 100 mg of 2 (0.122 mmol) were suspended in 15 ml of DME and 46 mg of benzimidazole (BzIm, 3 eq.) were added. The mixture was heated to 60 °C for 3.5 h and stopped when the red suspension had become a yellow solution and a yellow precipitate had formed.
The mixture was filtered while still hot. A bright yellow solid of 4 was collected and dried in vacuo. The crude product was purified by loading a CH 3 OH solution of 4 onto a chromatofix C18 filter. 
Synthesis of [ReBr 2 (CO) 2 (4,4 -Mebipy)] (8)
. 100 mg of 2 (0.122 mmol) were suspended in 15 ml of DME and 28 mg of 4,4'-dimedthyl-2,2'-bipyridine (4,4'-Mebipy, 1.25 eq.) were added. The suspension was heated to 60 °C for 3.5 h and stopped when the red suspension had become a deep red solution. The mixture was allowed to cool to room temperature (RT) and then filtered. 
Synthesis of [ReBr 2 (CO) 2 (phd)] (9)
. 100 mg of 2 (0.122 mmol) were suspended in 15 ml DME and 93 mg of 1,10-phenantroline-5,6-dione (phd, 1.25 eq.) were added. The suspension was heated to 60 °C for 3.5 h and stopped when the red suspension had become a deep red solution. The mixture was allowed to cool to RT and then filtered. The dark red solution was dried in vacuo leaving 9 as a dark red solid. The crude product was recrystallized from a CH 2 Cl 2 /hexane mixture. Yield: 60 mg, 81%. Anal. Single crystals suitable for x-ray diffraction were grown by slow diffusion of ether into an acetone solution of the compound giving dark red crystals.
Results and Discussion.
Synthesis of Complexes.
A summary of the reactions of 2 with different mono-, bi-and tridentate ligands is given in scheme 2.
As we have previously shown, complex 2 reacts well with monodentate nitrogen containing aromatic ligands. 1 Ellipsoids are drawn at 50% probability. Hydrogen atoms are omitted for clarity. Atoms labeled with underscore ( _ ) are symmetry generated. With the exception of 2 all complexes are insoluble in water. However, stock solutions of 2 in water were found to generate an inactive form of the complex due to the rapid CO release from this compound. Thus solutions of 2 were prepared in methanol while stock solutions of 3-13 were prepared in DMSO. The final methanol or DMSO content of the buffered aqueous solution never exceeded 0.5%.
The conversion of Mb to carbon monoxide myoglobin (MbCO) was followed over time by measuring the changes in the absorption spectra of the Q band region of this protein at pH 7.4, 6.3 and 5.8 after addition of the Re II complex. The maximal absorption peak of Mb at 560 nm was rapidly converted over time to spectrum of MbCO, with two maximal absorption peaks at 540 and 578, respectively. A typical spectrum is shown in figure 3 . Only compounds bearing monodentate ligands (i.e. compounds 2-7) elicited the spectral changes associated with CO release. All other complexes bearing a N∩N type of ligand did not liberate CO. The amount of MbCO formed over time after addition of the Re II complex to the Mb solution was calculated according to the known extinction coefficients. 19 The MbCO concentration was directly related to the equivalents of CO released from the compounds and these were plotted as a function of time. Figure 4 shows the pH-dependent rate of The rate of CO loss from 2-7 was found to be pH-dependent with half lives (t 1/2 ) under physiological conditions (pH 7.4) varying from ca. 6 (for 2) to 43 min (for 6, understood. It may be due to a cis-labilizing effect of potential π-donors such as H 2 O which could substitute the bound bromide ions. Also, as previously suggested, 51 this type of pH-dependence may point to an associatively activated substitution mechanism. This is reasonable in light of the fact that all
Re species investigated are 17e-complexes.
Complex 2 was found to be the most rapid CO-releasing molecule (CO-RM) in all cases while the imidazole adducts the slowest. The overall order for the rate of CO release is: 2 > 4 ≈ 7 > 5 > 3 ≈ 6. At pH and glucose omission was tested and the cells were incubated for 16 h in glucose-free welloxygenated medium at pH of 6.0. Thereafter "reperfusion" step was simulated by replacing the medium by that containing 5 mM glucose at pH of 7.4. As in the "ischemia-reprfusion" protocol Re II complexes were added immediately after the medium replacement and the incubation duration fixed to 12 h.
Similar to that under normoxic conditions, cell viability was not affected by these manipulations, except for complex 5, which again lead to over 90% cell mortality (data not shown). Finally the cells were exposed to a simulated ischemia-reperfusion. Ischemic condition was simulated by exposing the cells to glucose-free medium of pH 6.0 in hypoxic incubator (1% O 2 , 5% CO 2 and 94% N 2 ). After 16 h of "ischemia" the selected Re II complexes 2, 5, 6 and 7 at final concentration of 30 µM were administered into the cell culture medium as it was changed to high glucose well-oxygenated medium of pH 7.4, namely at the "onset of reperfusion". Their cytoprotective efficacy was tested 12 h after the administration. Exposure of cells to the "ischemia-reperfusion" procedure reduced cell viability to ~75%
(i.e. 25% dead cells) in the absence of Re II complexes (control in figure 5 ). Addition of complex 2 during "reperfusion" incresed cell survival by 67% (~9% dead cells) and complex 6 by 83% (~4% dead cells), while complexes 5 and 7 displayed no significant protective effect (see figure 5 ). to the "ischemia-reperfusion" protocol without Re II complex displying ca. 25% dead cells (control in figure 5 ). In the third row the number of dead cells was reduced by complex 6 added during the reperfusion phase. None of the compounds tested was able to reduce cell mortality when present in the culture during the hypoxic phase alone. Taken together, these findings indicated that the CO released from the Re II complexes attenuated the oxidative toxicity during reoxygenation but was unable to support cell survival under conditions of oxygen deprivation as CO further reduced O 2 availability.
Atomic absorption spectroscopy (AAS) measurements indicated that complexes 2, 6 and 7 did not enter the cells through the cell surface membrane during a 3 h incubation period (data not shown).
Compound 5, on the contrary, was actively taken into the cells with the uptake rate of ~ 40 µmol/(10 6 cells*h). Rhenium concentration in the medium decreased to <7-8 µM after 2 h of exposure suggesting that the compound was accumulating in the cells against the gradient and/or rapidly metabolised. Of note, accumulation of complex 5 was not followed by an immediate 90% mortality suggesting that not the compound itself, but rather the product(s) of its metabolism (such as 4-methylpyridine), were the cause of its elevated toxicity. These findings indicate that the cytoprotective action exerted by 2 and 6 may be attributed to the extracellular release of CO while the high toxicity of complex 5 may be related to its membrane permeability and accumulation into the cells. Our results further suggest that the rate of CO release is not a determining factor for the protection of NRCs. Both complex 2 (t 1/2 of CO loss = ca. 6 min) and 6 (t 1/2 = ca. 43 min) protect cardiomyocytes in our "ischemiareperfusion" protocol. Compound 7 (t 1/2 = ca. 17 min) displayed no significant protection while 5 (t 1/2 = ca. 24 min) was toxic. With regard to the cytoprotective effect, all synthesized Re II complexes contain two molecules of carbon monoxides (CO). The myoglobin assay indicated that all complexes tested released one CO per molecule within 2 hours albeit at different rates (see table 3 ). Given the fact that the tested complexes (with the exception of 5) remain outside the cells, it must be assumed that the released CO that is known to be lipid soluble, readily enters the cells to exert its biological function. 51 Whether the second CO will be released later during the 12 h of reperfusion is not known at present. It could be that metabolic interactions in the medium leads to structural rearrangements entailing release of the second CO molecule with progressing time. Anyhow, the results clearly indicate that complex 6 with the slowest CO release rate (t 1/2 = ca. 43 min) offers the most extensive protection as compared to the slower CO releasing complex 2. Complex 7 displays no protection and the most lipophilic complex 5, which enters the cells, seems to precipitate cell mortality (figure 5). It is possible that in these two cases toxic properties may compete and outweigh the beneficial effects of CO (pyridines are cytotoxic themselves).
Conclusion.
The 
